Business News • PR NewsWire • Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials

Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials

Novartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical Trials

BASEL, Switzerland, June 3, 2019 /PRNewswire/ -- Novartis announced today new data and clinical trial updates in NSCLC at the ASCO 2019 Annual Meeting. This includes primary efficacy results from the GEOMETRY mono-1 Phase II clinical trial demonstrating that investigational MET inhibitor...

View More : https://www.prnewswire.com:443/news-releases/novartis-shows-growing-strength-in-lung-cancer-innovation-with-new-capmatin...

Releted News by prnewswire

The Opening of the Emerald Bay Hotel Further Upgrades the Groundbreaking Archeology Themed Cambrian Town Happy World Resort

Targovax Announces Publication of in vivo Abscopal Effect of ONCOS-102 and Keytruda Combination

EAACI Annual Congress 2019, S. aureus es un factor de riesgo que contribuye a las alergias alimenticias

Granite Announces Departure of Chief Financial Officer

Johnson Controls International plc announces preliminary results of cash tender offer